Targeting HIV-1 protease: a test of drug-design methodologies (Q40532115)

21 September 2017

1 reference

title

Targeting HIV-1 protease: a test of drug-design methodologies (English)

1 reference

21 September 2017

2

1 reference

21 September 2017

West ML

1

1 reference

21 September 2017

publication date

1 February 1995

1 reference

Trends in Pharmacological Sciences

21 September 2017

published in

1 reference

21 September 2017

volume

16

1 reference

21 September 2017

issue

2

1 reference

21 September 2017

page(s)

67-75

1 reference

The 3-D structure of HIV-1 proteinase and the design of antiviral agents for the treatment of AIDS.

21 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2988980-4

7 January 2021

HIV protease as an inhibitor target for the treatment of AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2988980-4

7 January 2021

Structure and Function of Retroviral Proteases

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2988980-4

7 January 2021

Human immunodeficiency virus type 1 protease inhibitors irreversibly block infectivity of purified virions from chronically infected cells

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2988980-4

7 January 2021

Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2988980-4

7 January 2021

Structure-based inhibitors of HIV-1 protease

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2988980-4

7 January 2021

Structure of complex of synthetic HIV-1 protease with a substrate-based inhibitor at 2.3 A resolution

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2988980-4

7 January 2021

Antiviral and pharmacokinetic properties of C2 symmetric inhibitors of the human immunodeficiency virus type 1 protease

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2988980-4

7 January 2021

Preclinical evaluation of antiviral activity and toxicity of Abbott A77003, an inhibitor of the human immunodeficiency virus type 1 protease

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2988980-4

7 January 2021

Rational design of peptide-based HIV proteinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2988980-4

7 January 2021

HIV proteinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2988980-4

7 January 2021

Discovery of a novel class of potent HIV-1 protease inhibitors containing the (R)-(hydroxyethyl)urea isostere

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2988980-4

7 January 2021

Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2988980-4

7 January 2021

A pharmacokinetic evaluation of HIV protease inhibitors, cyclic ureas, in rats and dogs

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2988980-4

7 January 2021

In vitro anti-human immunodeficiency virus (HIV) activities of transition state mimetic HIV protease inhibitors containing allophenylnorstatine

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2988980-4

7 January 2021

Structure-based design of HIV protease inhibitors: 4-hydroxycoumarins and 4-hydroxy-2-pyrones as non-peptidic inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2988980-4

7 January 2021

Different requirements for productive interaction between the active site of HIV-1 proteinase and substrates containing -hydrophobic*hydrophobic- or -aromatic*pro- cleavage sites

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2988980-4

7 January 2021

Molecular modeling software and methods for medicinal chemistry

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2988980-4

7 January 2021

CGP 53437, an orally bioavailable inhibitor of human immunodeficiency virus type 1 protease with potent antiviral activity

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2988980-4

7 January 2021

Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2988980-4

7 January 2021

Hydroxyethylamine analogues of the p17/p24 substrate cleavage site are tight-binding inhibitors of HIV protease

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2988980-4

7 January 2021

New hydroxyethylamine HIV protease inhibitors that suppress viral replication

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2988980-4

7 January 2021

Specificity mapping of HIV-1 protease by reduced bond inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2988980-4

7 January 2021

Non-peptidic anti-AIDS agents: inhibition of HIV-1 proteinase by disulfonates

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2988980-4

7 January 2021

Design of a well-absorbed renin inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2988980-4

7 January 2021

HIV-1 protease inhibitors based on hydroxyethylene dipeptide isosteres: an investigation into the role of the P1' side chain on structure-activity

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2988980-4

7 January 2021

A series of potent HIV-1 protease inhibitors containing a hydroxyethyl secondary amine transition state isostere: synthesis, enzyme inhibition, and antiviral activity

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2988980-4

7 January 2021

Flavones are inhibitors of HIV-1 proteinase

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2988980-4

7 January 2021

A novel nonpeptide HIV-1 protease inhibitor: elucidation of the binding mode and its application in the design of related analogs

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2988980-4

7 January 2021

Generation and characterization of a human immunodeficiency virus type 1 (HIV-1) mutant resistant to an HIV-1 protease inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2988980-4

7 January 2021

Human immunodeficiency virus type 1 (HIV-1) inhibitory interactions between protease inhibitor Ro 31-8959 and zidovudine, 2',3'-dideoxycytidine, or recombinant interferon-alpha A against zidovudine-sensitive or -resistant HIV-1 in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2988980-4

7 January 2021

10.1016/S0165-6147(00)88980-4

Identifiers

DOI

1 reference

21 September 2017

1 reference